Dianthus Therapeutics, Inc. (DNTH) stock analysis

In our weekly check, Dianthus Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 12.

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DNTH.

What our checks show for DNTH

Red flags

Warning signs

Strengths

Similar companies

SRRK · PTCT · COGT · EWTX · MANE · ERAS

Questions

What grade does Dianthus Therapeutics, Inc. (DNTH) have?

In our weekly check, Dianthus Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 12. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of DNTH stock?

This week's biggest flags for Dianthus Therapeutics, Inc.: Margins falling, Profits not backed by cash, Weak EPS forecast. In total 15 of 22 checks show a warning or a red flag.

What does Dianthus Therapeutics, Inc. do?

Dianthus Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DNTH.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis